Size, Share & Industry Analysis, By Type (PCR and Other Nucleic-Acid Kits, Antigen Detection Kits, Serology and Other Kits), By Application (Public Health and Reference Laboratories, Hospitals and Clinics, Research and Surveillance Programs), By Test Platform (Centralized Automated Systems, Decentralized Cartridge Systems, Open PCR and Other Formats), By Procurement Channel (Government and Multilateral Tenders, Direct Institutional Purchasing, Distributor and Other Channels), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Monkeypox Diagnostic Kit Market was valued at USD 662.2 million in 2025 and is estimated at USD 707.3 million in 2026. Revenue is projected to reach USD 1,197.8 million by 2034, corresponding to a 6.8% CAGR during 2026–2034.
The revenue boundary covers professional-use molecular and other validated mpox-specific diagnostic kits, including assay reagents, cartridges, extraction components sold with assays and single-use consumables supplied by test manufacturers. It excludes unrelated orthopoxvirus research materials, generic PCR instruments sold for other diseases, clinical consultation fees and vaccination. The publisher forecast measures kit sales rather than the total value of every laboratory service associated with suspected mpox cases.
WHO emergency listings document a widening range of qualified assays. Abbott Alinity m was listed in October 2024, followed that month by Roche cobas MPXV and Cepheid Xpert Mpox. WHO subsequently listed automated and conventional nucleic-acid tests from manufacturers in Korea, China, Australia and the United States. These additions broaden procurement options but do not establish audited worldwide diagnostic-kit sales or prove that every listed test is interchangeable across mpox clades.
WHO and PAHO surveillance data show a geographically uneven testing requirement. The Americas accounted for 39.7% of 185,565 confirmed cases reported globally through June 2026, while the African region accounted for 37.3%. Case counts are not revenue shares: assay pricing, laboratory infrastructure, purchasing arrangements and unconfirmed infections create large differences between epidemiological burden and manufacturer income. Public procurement and stock rotation therefore matter alongside clinical test volume.
CDC guidance updated in February 2026 recommends real-time PCR on skin-lesion specimens, with two swabs from each lesion to preserve material for clade-specific work. WHO identified Xpert Mpox as a near-point-of-care cartridge with results in under 40 minutes and Roche cobas MPXV as a higher-throughput assay capable of results in under two hours. This contrast drives purchasing decisions between decentralized district sites and centralized reference laboratories.
Source: WHO test listings; CDC diagnostic guidance; PAHO 2026 surveillance.
The study measures revenue from monkeypox virus diagnostic assay kits and compatible dedicated consumables supplied to professional laboratories, hospitals and public-health buyers; it does not count vaccine sales or unrelated diagnostic-platform turnover.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | PCR and Other Nucleic-Acid Kits; Antigen Detection Kits; Serology and Other Kits |
| By Application | Public Health and Reference Laboratories; Hospitals and Clinics; Research and Surveillance Programs |
| By Test Platform | Centralized Automated Systems; Decentralized Cartridge Systems; Open PCR and Other Formats |
| By Procurement Channel | Government and Multilateral Tenders; Direct Institutional Purchasing; Distributor and Other Channels |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Spain; Germany; China; India; Brazil; Mexico; Democratic Republic of the Congo; Nigeria |
| Key Market Players | Abbott Molecular Inc.; Roche Molecular Systems Inc.; Cepheid; KH Medical Co., Ltd.; UStar Biotechnologies (Hangzhou) Ltd.; Shanghai ZJ Bio-Tech Co., Ltd.; HA TECH PTY LTD; Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.; Taizhou Cowingene Biotech Co., Ltd.; Jiangsu Bioperfectus Technologies Co., Ltd.; DiaCarta Inc.; Siemens Healthineers |
PCR assay reagents and cartridges are counted when marketed for monkeypox virus detection from patient specimens. Dedicated extraction consumables supplied in the same kit are included, while reusable GeneXpert, cobas and Alinity instruments are excluded unless sold specifically as part of a bundled mpox-only package. WHO emergency-use listings demonstrate eligible assay products but are not evidence that the entire installed instrument base is mpox revenue.
The Type dimension classifies the test chemistry, Application classifies the primary clinical or public-health purpose, Test Platform classifies operating architecture, and Procurement Channel identifies the first institutional purchasing route. Each 2025 kit transaction is assigned to one member of each dimension to avoid double counting. The model excludes vaccine procurement, antiviral therapy, unrelated multiplex panels without an identifiable mpox component and private consultation charges.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Ongoing clade I and II surveillance | High | +3.00% | High | High | Medium |
| Expansion of WHO-listed molecular assays | High | +2.10% | High | Medium | Medium |
| Near-patient cartridge deployment | Medium-High | +1.60% | Medium | High | High |
| Government laboratory preparedness procurement | Medium | +1.30% | High | Medium | Medium |
| Clade differentiation and repeat confirmation | Low-Medium | +0.70% | Medium | Medium | High |
| Others (training, logistics, multiplex development) | Low | +0.40% | Low | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Outbreak-related order volatility | High | -1.10% | High | Medium | Medium |
| Specialized specimen and PCR infrastructure | Medium-High | -0.70% | High | Medium | Low |
| Tender pricing and limited donor budgets | Medium | -0.30% | Medium | High | High |
| Others (expiry, validation, shipment costs) | Low | -0.20% | Medium | Low | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 6.8% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
PAHO reported 185,565 confirmed mpox cases globally through June 2026, with cases distributed across 145 countries and territories. New clade Ib detections in the Americas have prompted laboratories to preserve clade-discrimination capacity rather than rely solely on older clade II workflows. Because suspected cases must be confirmed from lesions, changes in case incidence affect swab and reagent consumption directly. Procurement also includes reserve inventories for outbreaks that may not generate immediate test volume, especially at national reference laboratories.
WHO listed Abbott Alinity m MPXV in October 2024 and subsequently added Roche, Cepheid, KH Medical, UStar and other manufacturers. Its September 2026 listing of DiaCarta QuantiVirus MPXV gave buyers another evaluated assay option. Emergency listing supports procurement decisions where local regulatory pathways are limited, but it is not a guarantee of national reimbursement or a universal performance endorsement. Manufacturers must still document clade coverage, specimen compatibility and quality systems to win tenders across differing regulatory jurisdictions.
WHO describes Cepheid Xpert Mpox as an automated PCR test yielding results in under 40 minutes on compatible GeneXpert systems. Decentralized facilities can therefore avoid some delays associated with shipping lesions to central laboratories. However, the WHO listing described detection of clade II, so procurement for clade I surveillance requires confirmation of the specific assay indication or an additional testing pathway. Service availability, cartridge supply and training determine whether theoretical speed translates into faster isolation decisions.
CDC guidance from February 2026 specifies lesion material and recommends two swabs per lesion for possible further testing. Its consumer guidance states that only a healthcare provider can order testing and that routine testing is directed to people with a compatible rash. These conditions support professional collection kits, laboratory logistics and trained clinical channels rather than unsupported mass-market self-testing claims. Poor sampling can also cause repeat collection and waste, raising the effective cost per usable result.
WHO documented that only 37% of suspected cases in the Democratic Republic of the Congo had been tested during the 2024 response. Laboratory access gaps create potential for equipment and reagent procurement, but funding depends on donor programs, health ministry budgets and field logistics. Meanwhile, regions with lower current incidence may rotate stock without replenishing it at peak-outbreak rates. Manufacturers with adaptable production schedules can respond more efficiently than suppliers dependent on fixed emergency orders.
Sources: WHO Emergency Use Listing announcements; CDC February 2026 diagnostic guidance; PAHO July 2026 surveillance; WHO October 2024 response.
WHO listed UStar EasyNAT and PortNAT in May 2025 with detection of clades I and II, including Ib. In contrast, its 2024 Xpert Mpox description specified clade II detection. Procurement teams consequently need assay-specific validation rather than treating all mpox PCR kits as equivalent. The 2026 WHO report of recombinant Ib/IIb virus in India and the United Kingdom reinforces the value of confirmatory sequencing and updated target evaluation when genomic changes challenge older primer designs.
Roche cobas MPXV runs on cobas 6800/8800 platforms and WHO reported results in under two hours, making it suitable for laboratories processing many samples. Cepheid Xpert Mpox uses a compact cartridge workflow with a sub-40-minute result. The economic comparison depends on installed equipment, batch utilization, transport time and procurement pricing rather than turnaround alone. Public-health systems may buy both formats to keep central confirmation available while placing rapid instruments closer to suspected cases, particularly in districts with difficult specimen transport.
WHO reported its twelfth listed MPXV assay in December 2025 and added DiaCarta QuantiVirus in September 2026. More listed products create price and supply alternatives for procurement agencies, while the WHO prequalification portal separates pending applications from completed listings. Buyers should not infer authorization from an application under review. The shift favors manufacturers that publish clear intended-use language, documented specimen performance and production quality controls before seeking international distribution, with transparent labeling for each supported clade.
CDC instructs laboratories performing orthopoxvirus or mpox PCR to report results to state, tribal, local or territorial health departments. ECDC similarly asks countries to identify clades and share sequences through recognized repositories when possible. These requirements generate demand for confirmatory reagents, reference-laboratory workflows and information systems around the assay. They do not necessarily increase the number of patient tests one-for-one, because sequencing is usually concentrated in selected positive samples, and routine negative specimens do not all undergo genomic analysis.
The PAHO July 2026 update recorded 1,203 cases and three deaths in the Americas through July, while Africa retained a large share of cumulative global cases. High-income countries can procure tests for low-volume readiness, whereas African laboratories may face more infections but tighter purchasing budgets. Manufacturers serving both markets need differentiated packaging, reagent stability and distribution support. The result is a geographically mixed revenue pool rather than a direct mirror of reported case totals, with substantial differences in the average cost of laboratory consumables.
PCR and other nucleic-acid kits dominate the professional mpox testing pathway because WHO and CDC recommend molecular confirmation of lesion specimens. Antigen formats are relevant only when their sensitivity and intended use are validated for a particular setting. Serology has a different epidemiological role and cannot automatically replace PCR in suspected acute infection.
This group represented an estimated ~82% of 2025 revenue. WHO listings include Abbott Alinity m, Roche cobas MPXV, Cepheid Xpert Mpox and UStar assays, each with specified instruments and specimens. Molecular tests are favored for definitive confirmation, and procurement often includes controls and extraction components. The exact kit mix differs by whether a laboratory already owns a compatible instrument.
Antigen tests can offer shorter workflows without complex amplification equipment, but the available WHO emergency-listing evidence is concentrated in nucleic-acid assays. Public buyers require documented analytical sensitivity and clinical validation before using an antigen result to guide case management. Limited uptake is expected until robust performance is demonstrated for relevant clades and lesion sample types.
Antibody-oriented and research-use formats serve selected epidemiology or laboratory investigations rather than routine acute confirmation. CDC notes that real-time PCR is the diagnostic method used for suspected monkeypox. Cross-reactivity within orthopoxviruses and differences in immune response can complicate interpretation, so these kits occupy a smaller revenue pool and require carefully stated intended use.
The type mix should remain molecular-led through 2034 because regulatory guidance emphasizes viral DNA detection. Changes in reagent price, cartridge convenience and validated clade coverage will redistribute value within PCR rather than necessarily displace it.
The application split follows the principal reason a professional buyer orders mpox assay kits. Public-health and reference laboratories handle surveillance and confirmation, clinical providers use tests for patient management, and research programs use them for sequencing-linked investigation. The same specimen is allocated to its primary purpose to avoid double-counting purchases.
These institutions represented an estimated ~57% of 2025 revenue. CDC reporting requirements and WHO outbreak monitoring make central laboratories critical to case confirmation and clade identification. High-throughput assays support batch processing, while procurement through public budgets can cover both active case investigations and readiness inventories. Demand is therefore tied to public-health capacity as well as incidence.
Hospitals collect lesion swabs and order PCR when a compatible rash warrants testing. CDC advises clinicians to obtain two swabs from each lesion to allow additional testing where needed. Many hospitals send samples to commercial or public laboratories rather than operating an mpox-only platform, so clinical demand generates reagent purchases at the receiving laboratory without counting the hospital referral twice.
Specialized surveillance programs evaluate clade distribution, recombination and assay target performance. WHO described a recombinant Ib/IIb strain identified through sequencing in India and the United Kingdom, illustrating the need for targeted genomic follow-up. Such programs can purchase controls, typing assays and sample preparation materials, but their budgets are narrower than routine clinical confirmation and public-health case finding.
Application mix depends on how national systems assign specimen testing responsibilities. A decentralized program may move some procurement toward hospital laboratories, whereas central referral networks preserve reference-laboratory purchasing leadership.
The platform dimension classifies assay operation rather than chemistry or buyer identity. Centralized automated instruments handle high-volume workflows, cartridge systems support faster decentralized decisions, and open PCR formats use laboratory-installed thermocyclers. The classification avoids adding instrument sales unrelated to mpox kit revenue.
Roche cobas MPXV is intended for cobas 6800/8800 analyzers, and Abbott Alinity m MPXV uses the Alinity molecular platform. Centralized systems reduce manual handling when specimen volumes rise, but their economics depend on existing installations and batch utilization. A laboratory with few suspected cases may prefer referral testing rather than maintaining dedicated local stock.
WHO described Cepheid Xpert Mpox as an automated real-time PCR test returning results in under 40 minutes. Cartridge systems can shorten transport-related delays and reduce the number of separate preparation steps. Buyers must still check clade coverage and instrument availability, particularly when surveillance requires clade I differentiation or follow-up sequencing.
Conventional amplification kits can run on validated laboratory thermocyclers and may be useful where installed instruments are not tied to a single reagent supplier. WHO-listed products from multiple Asian manufacturers broaden procurement options. Their field performance still depends on extraction workflow, operator competence, contamination controls and locally approved intended use.
Centralized systems retain a meaningful value position, while decentralized cartridges gain relevance where the time to laboratory confirmation is long. Open formats remain important for national laboratories with established PCR expertise and tight reagent budgets.
Mpox diagnostic kits reach end users through government and multilateral tenders, direct institutional purchases and authorized distributors. Emergency-use listing can support procurement eligibility, but the actual purchasing authority depends on national registration rules and local budgets. The channel dimension records the first commercial sale of the kit.
Health ministries and public-health agencies buy assays for outbreak response, reference laboratories and reserve stocks. WHO emergency-use listing provides a quality assessment pathway for some international procurement. Tender cycles can be irregular, and quantities may be revised as cases decline or donor financing changes. Manufacturers therefore need flexible supply commitments and transparent expiry terms.
Commercial laboratories and hospital networks often purchase compatible reagents directly from instrument vendors or approved suppliers. Existing Alinity, cobas and GeneXpert installations influence ordering because laboratories seek to avoid separate validation costs. Direct sales can include training and technical support, although general-purpose instrument revenue is outside this kit market.
Local distributors help smaller laboratories obtain kits, transport media and controls where manufacturers lack direct sales teams. WHO documentation and national import requirements can determine which products enter the channel. Stock management is particularly important for remote laboratories facing intermittent case volumes, because expired reagents can erase the advantage of low tender prices.
Government contracts can dominate surge periods, while direct laboratory replenishment supports steadier ordering. Distributor economics are most sensitive to shipment size, shelf life and the cost of reaching regional laboratories.
Revenue follows laboratory purchasing capacity as well as reported mpox cases. The 2025 geographic shares below are modeled allocations; WHO and regional surveillance statistics measure infections, not manufacturer kit sales.
North America held an estimated ~35% of global kit revenue in 2025. The United States combines public-health reference laboratories with large commercial PCR providers, while Canada has national clade-identification capacity. CDC guidance updated in February 2026 requires lesion-swab testing and emphasizes reporting results to health authorities. Regional demand includes both routine suspected-case diagnosis and readiness procurement for new clade introductions. High labor costs and existing automated instruments support value per assay, although the region does not account for the largest share of global suspected infections.
CDC guidance dated 6 February 2026 says real-time PCR is used to diagnose mpox and recommends two swabs per lesion for possible clade-specific testing. Public-health and commercial laboratories provide testing, and results must be reported to health departments. This system sustains reagent demand for both clinical referrals and surveillance even when local case counts are limited. The FDA distinguishes cleared assays from tests available under emergency authorization.
Source: CDC.
The Public Health Agency of Canada confirmed the first national clade I case in Manitoba on 22 November 2024 through its National Microbiology Laboratory. Canadian public-health reporting later documented 2,236 cases across ten provinces and territories by September 2025, with most cases in Ontario, Quebec and British Columbia. Reference testing and molecular clade differentiation therefore remain important despite lower recent incidence than the 2022 peak.
Source: PHAC.
European laboratories face continued co-circulation of clades I and II. ECDC reported 102 clade I cases in April 2026 across eleven EU/EEA countries, alongside 23 clade II cases in seven countries. This creates demand for molecular confirmation, typing and selected sequencing even when most clinical infections are mild. Procurement is fragmented among national health systems, regional reference centers and hospital laboratories. Laboratories with established automated PCR instruments may prefer validated assays compatible with their installed equipment, while smaller networks use centralized referrals.
ECDC reported Spain had 33 of the EU/EEA clade I cases recorded in April 2026. The same agency documented ongoing circulation in sexual networks and recommended continued clade identification. Spanish regional public-health laboratories therefore require assays capable of differentiating relevant lineages and passing results into surveillance systems. Testing purchases may vary by region and season rather than follow a single national volume curve.
Source: ECDC.
Germany recorded 30 clade I cases during April 2026 according to ECDC, and its laboratories operate within a broader European reporting framework. The need to investigate suspected cases and distinguish clades supports molecular test consumption at specialist centers. However, case numbers alone do not reveal kit spending: reimbursement, procurement prices and the proportion of tests processed on existing automated platforms affect supplier revenue.
Source: ECDC.
Asia-Pacific contains a diverse group of manufacturers and testing systems. WHO emergency-use listings include products from UStar, Shanghai ZJ Bio-Tech, Jiangsu Macro & Micro-Test and Jiangsu Bioperfectus, while India has pursued domestic validation of mpox assays. These developments increase sourcing options for regional procurement and export. The WHO report on an Ib/IIb recombinant strain identified in India highlights the importance of updating primer targets and sequencing selected positive specimens. The region combines advanced automated laboratories with district facilities needing simpler extraction and transport arrangements.
WHO listed UStar EasyNAT and PortNAT assays in May 2025 for detection of clades I and II, including Ib. Further Chinese manufacturers received WHO listings later that year, expanding potential supply for international tenders. Chinese manufacturers compete on validated target coverage, packaging and availability, but WHO listing should not be equated with disclosed unit sales or market share. Chinese domestic surveillance and international export procurement have different tender cycles, distribution requirements and quality documentation.
Source: WHO.
Indian authorities approved domestic manufacturing of three mpox RT-PCR kits in August 2024 following ICMR validation, according to contemporaneous reporting. WHO subsequently described a recombinant Ib/IIb virus detected through PCR and genomic sequencing in a patient returning to India in September 2025. These events support local molecular preparedness and the need to maintain clade-aware confirmatory workflows, although validation does not demonstrate large commercial sales.
Source: WHO.
PAHO reported 1,203 mpox cases and three deaths in eleven American countries through July 2026. The regional surveillance network recorded clade Ib introductions in several countries, most linked to travel, and also described locally acquired infections. Latin American laboratory budgets vary substantially, so public-health tenders and shared reference facilities shape the addressable market. PCR assay availability must be paired with lesion-swab collection and reliable specimen transport. Brazil has state-level reporting systems, while Mexico participates in regional clade surveillance and cross-border case investigation.
Rio de Janeiro state reported eleven confirmed mpox cases by 24 February 2026 from 51 notifications, compared with 117 confirmed cases during all of 2025. The figures show how local suspected-case testing can continue even after a larger outbreak subsides. Procurement demand includes confirmatory reagents and controls for public laboratories, but state surveillance counts cannot be treated as national kit shipments or manufacturer revenue.
Source: Rio de Janeiro Health Secretariat.
PAHO documented imported clade Ib infections in Mexico during early 2026 and included the country among nine American nations with confirmed clade Ib cases by July. Laboratory confirmation is needed to distinguish introductions from sustained local spread. Public-health buyers therefore value assays with verified clade coverage, while sample referral and procurement arrangements determine whether testing is centralized or distributed across state facilities.
Source: PAHO.
African countries carry a substantial share of the global mpox burden, but reported cases translate into kit revenue only when laboratories have financing and operating capacity. WHO noted that just 37% of suspected cases in the Democratic Republic of the Congo had been tested during the 2024 response. Such gaps create a case for decentralized molecular systems, quality-assured assays and specimen transport investment. Middle Eastern demand is more concentrated in travel-related surveillance and established reference laboratories. Donor-funded purchasing and import logistics make regional revenue more volatile than the underlying infection burden.
WHO reported more than 30,000 suspected African mpox cases in 2024, with the largest numbers in the Democratic Republic of the Congo, Burundi and Nigeria. It also stated that only 37% of suspected DRC cases had been tested at that stage. Laboratory expansion could convert unmet diagnostic need into purchases, but shortages of staff, reagents and specimen transport may prevent every suspected case from generating a sale.
Source: WHO.
WHO identified Nigeria among the African countries with high suspected-case numbers during the 2024 outbreak response. Molecular confirmation remains important for distinguishing mpox from other rash illnesses and tracking viral lineages. Reference laboratories can use WHO-listed assays, but procurement depends on national funding, partner support and the availability of compatible instruments. Higher epidemiological burden should not be interpreted as evidence of proportionately higher manufacturer revenue.
Source: WHO.
WHO emergency-use listings provide documented evidence of commercial assay participation. The October 2024 listings for Abbott, Roche and Cepheid established options for large automated laboratories and decentralized cartridge workflows. Additional listings through September 2026 expanded the competitive set across Asia, Australia and the United States. Supplier comparisons must consider clade coverage, intended specimens, compatible instruments and procurement eligibility; listing dates do not reveal relative company sales or market concentration.
Abbott Alinity m MPXV and Roche cobas MPXV were among the first WHO-listed assays in 2024. The Abbott and Roche assays target professional laboratory use on established automated molecular platforms. Roche emphasizes high-throughput cobas 6800/8800 compatibility, while Abbott documentation specifies lesion-swab PCR. Installed instruments and laboratory validation influence repeat reagent orders, but neither listing establishes an mpox-only revenue share.
Cepheid Xpert Mpox uses GeneXpert automation and WHO reported a result in under 40 minutes. KH Medical RADIONE Mpox Detection Kit was listed in March 2025 for detection of both major clades. Their commercial opportunity lies in laboratories seeking simpler workflows, although performance claims must be checked against each specific product indication.
WHO added UStar EasyNAT and PortNAT in May 2025, Shanghai ZJ Lyo-PCR in September, Jiangsu Macro & Micro-Test in October, Taizhou Cowingene in November and Jiangsu Bioperfectus in December. These WHO-listed manufacturers offer distinct PCR formats, clade-typing capabilities and laboratory operating requirements. International distribution requires dependable quality systems and consistent supply rather than WHO listing alone.
WHO listed HA TECH NAT-17WE in October 2025 and DiaCarta QuantiVirus in September 2026. Siemens Healthineers was reported among Indian kit developers receiving manufacturing authorization in 2024. Their positioning differs by geography and regulatory pathway; a domestic manufacturing authorization is not equivalent to a WHO emergency-use listing or documented international market share.
Competition is structured around installed platform compatibility and public procurement. Laboratories operating Alinity, cobas or GeneXpert instruments can reduce implementation work by purchasing validated matching reagents. Buyers establishing new district capacity instead compare cartridge cost, extraction needs, operator training and sample throughput. WHO-listed Chinese and Korean manufacturers broaden options for laboratories without a single-vendor instrument contract, subject to national authorization and performance evaluation.
New entrants in the 2026 mpox diagnostic-kit market face two commercial constraints. First, outbreak demand can rise sharply and then contract, leaving suppliers with excess inventory or expiring kits. Second, clade coverage and specimen labeling vary across products, so public purchasers cannot assume one PCR kit replaces another without review. The WHO listing portal separates products under evaluation from completed listings; procurement agencies should use that distinction when building supplier panels and contingency stocks.
September 2026: WHO listed DiaCarta QuantiVirus MPXV Test Kit under its Emergency Use Listing procedure on 9 September 2026. The announcement expanded the set of evaluated diagnostic products available to procurement agencies responding to mpox. The listing is a quality-assessment milestone, not evidence of the manufacturer's global sales or an unrestricted authorization in every country. Source
May 2026: ECDC reported continued European clade I circulation in April 2026, with 102 cases across eleven EU/EEA countries. Spain and Germany accounted for 33 and 30 cases respectively. The update supported continued molecular confirmation and clade differentiation in public-health laboratories rather than assuming the decline in clade II infections removed the need for testing. Source
February 2026: CDC updated clinical mpox testing guidance on 6 February 2026, confirming real-time PCR as the diagnostic method and recommending two swabs from each lesion. The update supports professional-use molecular kits and additional clade testing when needed. It also emphasizes laboratory referral and appropriate collection rather than routine consumer self-testing without clinical assessment. Source
December 2025: WHO announced that Jiangsu Bioperfectus had obtained the twelfth Emergency Use Listing for an MPXV in vitro diagnostic. Its Monkeypox Virus Fast Real Time PCR Kit added another evaluated molecular assay to the procurement pool. The listing illustrates how multiple manufacturers entered the market after the first emergency-use decisions in 2024. Source
November 2025: WHO listed the Cowingene Monkeypox Typing Detection Kit, manufactured by Taizhou Cowingene Biotech, on 3 November 2025. The WHO-listed Cowingene product broadened options for laboratories needing typing-oriented molecular diagnostics. Public buyers still need to examine the kit's validated specimen and intended-use conditions before substituting it for routine clinical confirmation assays. Source
May 2025: WHO added UStar EasyNAT and PortNAT on 14 May 2025, both described as detecting clades I and II, including Ib, from lesion swabs. The two workflows extend procurement options for different laboratory settings. Their listings also demonstrate why clade-specific claims and operating requirements should be checked at the individual product level. Source
The Monkeypox Diagnostic Kit Market is forecast to rise from USD 707.3 million in 2026 to USD 1,197.8 million by 2034, equivalent to 6.8% CAGR. Growth depends on sustained molecular preparedness, new clade surveillance and replenishment of qualified test stocks rather than continuous peak-outbreak testing volumes.
| Forecast Variable | 2026 Starting Condition | Effect Through 2034 |
|---|---|---|
| Clade surveillance | Clades I and II circulating | Maintains confirmatory and typing demand |
| WHO-qualified supply | More than twelve listed assays by 2026 | Broadens procurement competition |
| Decentralized testing | GeneXpert and other automated formats | Reduces referral delay where deployed |
| Specimen workflow | Lesion swabs remain standard | Supports professional collection channels |
| Government budgets | Outbreak-dependent tenders | Creates order volatility |
| Assay validation | Clade coverage varies by product | Rewards updated target design |
In the early forecast period, public-health systems are likely to maintain reserve reagent stocks and expand clade-aware testing capacity following the WHO listings of 2024–2026. Procurement volume will not track case numbers mechanically: some jurisdictions operate high-value automated platforms with relatively few patients, while heavily affected countries may lack financing to test all suspected infections. WHO documentation of a 2024 DRC testing gap illustrates why infrastructure and purchasing capacity must develop together.
Between 2029 and 2031, cartridge formats may gain share in district laboratories where specimen transport creates long confirmation delays. Cepheid's WHO-listed sub-40-minute workflow illustrates the clinical benefit, but deployment economics include instrument availability, maintenance, staff training and cartridge supply. Centralized systems such as Roche cobas retain advantages for large batches, and open PCR kits offer flexibility to reference laboratories with validated equipment. Both centralized and decentralized molecular formats can coexist within a national testing network through 2034.
The later forecast period will depend on assay adaptation to changing viral lineages, surveillance funding and inventory replacement cycles. WHO reported a recombinant Ib/IIb virus investigated in India and the United Kingdom, supporting continued genomic monitoring of diagnostic targets. Companies with documented quality systems and clear clade claims can compete for public tenders, while unvalidated self-test formats face substantial regulatory barriers. No public source reviewed discloses an audited worldwide total of mpox kit revenue.
North America is expected to remain the largest value market under the modeled base-year allocation, while Africa has the greatest opportunity to close diagnostic-access gaps if procurement financing improves. Europe will require ongoing typing capacity as clade I circulation continues, and Asian manufacturers should expand the set of internationally eligible assay suppliers. Price competition can lower revenue per test even as test availability rises, limiting the translation from laboratory throughput into market value.
Coverage includes professional mpox assay manufacturers, laboratory users, surveillance authorities and procurement routes, with 2025 revenue as the base year.
The global market totaled **USD 662.2 million in 2025** under the publisher's kit-revenue boundary. The estimate includes professional mpox assay kits and dedicated consumables, but excludes unrelated laboratory equipment, vaccines and clinical consultation fees. Public surveillance figures measure cases rather than sales and cannot independently validate the manufacturer-revenue total.
Worldwide kit revenue is forecast at **USD 1,197.8 million by 2034**, rising from **USD 707.3 million in 2026**. The projected 6.8% compound annual growth reflects continuing molecular surveillance, expanded qualified supplier choice and procurement readiness, tempered by uneven outbreaks and public-health funding constraints.
PCR and other nucleic-acid kits led with an estimated **82% of 2025 revenue**. WHO and CDC guidance prioritize molecular detection from lesion material for clinical confirmation. The percentage is a modeled product-mix allocation, not a disclosed audited split across manufacturers or national procurement systems.
Public Health and Reference Laboratories accounted for an estimated **57% of 2025 kit revenue**. They process confirmatory specimens, maintain outbreak readiness and support clade surveillance. Hospitals also order tests, but many refer samples to centralized laboratories, so referrals should not be counted as separate kit sales.
North America represented an estimated **35% of global kit revenue in 2025**. The allocation reflects established molecular platforms, public-health procurement and commercial laboratory capacity. Africa reports a large disease burden, but infections do not translate directly into equivalent sales when testing access and budgets are constrained.
Yes. CDC clinical guidance updated on **6 February 2026** identifies real-time PCR as the diagnostic method and recommends lesion specimens. WHO likewise describes nucleic-acid amplification as the standard confirmation approach. Test interpretation depends on proper collection, specimen handling and the assay's validated intended use.
WHO documentation shows that clade coverage differs by individual assay and intended-use labeling. WHO described UStar EasyNAT and PortNAT as detecting both major clades, including Ib, while its 2024 Xpert Mpox description specified clade II. Laboratories should examine each manufacturer's current labeling and local authorization before using a kit for clade differentiation or excluding infection.
WHO-listed manufacturers include Abbott Molecular, Roche Molecular Systems, Cepheid, KH Medical, UStar, Shanghai ZJ Bio-Tech, HA TECH, Jiangsu Macro & Micro-Test, Taizhou Cowingene, Jiangsu Bioperfectus and DiaCarta. Their products differ in automation, targets and sample requirements; listing status does not disclose market share.
A cartridge integrates several steps on a compatible automated instrument and can reduce operator handling; WHO reports Xpert Mpox results in under 40 minutes. Centralized assays such as Roche cobas MPXV are designed for larger laboratory workflows. Selection depends on throughput, installed equipment, clade coverage and total procurement cost.
No. WHO emergency-use listing assesses specified quality, safety and performance evidence to support procurement during a health emergency. Individual countries can have separate authorization, import and reimbursement requirements. The WHO portal also distinguishes completed listings from applications still undergoing assessment, which are not endorsements.
Outbreak-related order volatility, constrained laboratory access, reagent shelf life and tender pricing all limit sales growth. WHO reported that only 37% of suspected DRC cases had been tested during the 2024 response. Additional laboratory infrastructure and sustainable funding are needed before unmet diagnostic need becomes recurring purchases.
The **2026–2034** period captures replacement of preparedness inventories, expansion of decentralized molecular testing and continued clade surveillance. The 2026–2034 forecast does not assume uninterrupted emergency-level case volumes across all regions. Public-health purchasing may rise sharply during outbreaks and decline afterward, so annual sales can fluctuate around the projected long-term 6.8% growth path.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.